Concord Medical Services (ADR) (CCM)
Provides oncology care, radiotherapy infrastructure, and cloud services across China.
TWO Urges Stockholders to Vote FOR the CCM Transaction Today; Failure to Approve Risks a Significant Decline in TWO's Stock Price
NEW YORK--(BUSINESS WIRE)--TWO Urges Stockholders to Vote FOR the CCM Transaction Today; Failure to Approve Risks a Significant Decline in TWO's Stock Price.
ComplianceCow to Demonstrate Generative AI-Powered CCM 3.0 Controls in ServiceNow IRM
SAN FRANCISCO--(BUSINESS WIRE)--ComplianceCow, an agentic automation platform for enterprise security GRC teams, will host a live webinar on June 22, 2026 demonstrating how Generative AI transforms natural language inputs into deterministic, auditable Continuous Controls Monitoring (CCM) 3.0 controls inside ServiceNow IRM. The session, titled From Prompt to Production: Building Automated CCM 3.0 Controls with Generative AI in ServiceNow IRM, runs from 1:30 to 2:00 pm ET and is open to complianc.
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹ Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives Participating pharmacists expected to gain access to new clinical service revenue opportunities TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.
Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025
BEIJING, April 29, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission ("SEC"). An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
Concord Medical Schedules 2025 Annual Meeting of Shareholders
BEIJING , Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time).
Ethic Inc. Sells 47,560 Shares of CCM Affordable Housing MBS ETF $OWNS
Ethic Inc. lowered its stake in shares of CCM Affordable Housing MBS ETF (NYSEARCA:OWNS) by 65.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,227 shares of the company's stock after selling 47,560 shares
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Investment Company CCM Starts a Position in KLA Corporation. Is the Stock a Buy?
On October 10, 2025, CCM Investment Advisers LLC disclosed a new position in KLA Corporation (KLAC 5.64%), acquiring 11,189 shares for an estimated $12.07 million based on the quarterly average price in the third quarter of 2025.
Investment Company CCM Opened a Position in Oracle. Does This Mean the Stock Is a Buy?
Financial management company CCM Investment Advisers reported a new position in Oracle Corporation (ORCL -1.33%) valued at $13.99 million as of September 30, 2025, according to an SEC filing dated October 10, 2025.
Investment Company CCM Initiated a Position in AMD. Is the Stock a Buy?
CCM Investment Advisers disclosed a new position in Advanced Micro Devices (AMD -7.78%) in its October 10, 2025 Securities and Exchange Commission filing. The estimated $11.13 million purchase occurred in the third quarter of 2025.
Concord Medical Reports Financial Results for the First Half of 2025
BEIJING , Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1].
Sun Valley Investments AG Announces Acquisition of Securities of Canagold Resources Inc.
VANCOUVER, British Columbia--(BUSINESS WIRE)--This news release is related to the common shares of Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM). Sun Valley Investments AG, a Private Investment Firm (the “Acquiror”), and a related party, Goldlogic Corp. (“Goldlogic”), announce the acquisition of 2,325,581 flow-through shares of the Company (each a “FT Share”) that qualify as flow-through shares for the purposes of the Income Tax Act (Canada) at a price of CAD$0.43 per FT Shar.
Concord Healthcare Announces Official Release of the Proton Therapy Large Model
BEIJING , May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology.
Concord Medical Files Annual Report on Form 20-F for Fiscal 2024
BEIJING , April 25, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING , Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment (the "Registration Certificate") made by the Company's equipment supplier on December 6, 2024. As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022.
Concord Medical Schedules 2024 Annual Meeting of Shareholders
BEIJING , Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2024 annual general meeting of shareholders (the "Meeting") on December 27, 2024, at 10:00 a.m. (Beijing Time).
Concord Medical Reports Financial Results for the First Half of 2024
BEIJING , Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING , Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares.
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING , July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio of one (1) ADS representing three (3) Class A ordinary shares to a new ADS Ratio of one (1) ADS representing thirty (30) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on July 30, 2024 (U.S. Eastern Time).